Business
Cannabics Pharmaceuticals Places IP & Subsidiary Within the Company
Cannabics Pharmaceuticals Places IP & Subsidiary Within the Company.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Places IP & Subsidiary Within the Company\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Places IP & Subsidiary Within the Company\nPR Newswire\nBETHESDA, Maryland, Feb. 29, 2016\n\n\n\nBETHESDA, Maryland, Feb. 29, 2016 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) announced that it has placed its wholly owned subsidiary \"Grin Ultra Ltd.\" and all accompanying Intellectual Property rights into its public company. \n\n\nThe Intellectual Property involves the company's IP filed with the USPTO entitled \"A Method of in Vitro High Throughput Screening of Cancer Biopsies with Cannabinoid Extracts\". This system analyzes cancer cells taken directly from patient biopsies, and then tests them against a multitude of cannabinoid combinations for anti-tumor activity via the High Throughput Screening process. These natural extracts could also be tested in conjunction with already approved and common synthetic drugs for patients who undergo chemotherapy for the most personally tailored therapy. This multilayer method produces a large-scale database that will capture the knowledge gained as to the unique effects of different combinations of cannabinoid compounds on diverse malignancies. \n\nGrin Ultra Ltd. is the Company's wholly owned subsidiary created in 2014, and is specifically licensed by the Israeli Health Ministry for cannabinoid research, allowing the company unparalleled opportunities to conduct its cutting edge R&D. \n\nSaid Itamar Borochov, CEO: \"We can now proceed forward with all our IP, Subsidiary and energies within the Company moving confidently ahead to our next goals. We also have found the right \"fit\" of institutional investors in Aloni-Haft Group, one of Israel's largest global investment banks, which has brought together investors from the pharmaceutical and bio-tech industries who understand both our science and our vision for growth and upscaling through our next contemplated phases.\"\n\nAbout Cannabics Pharmaceuticals Inc.\n\nCannabics Pharmaceuticals (CNBX), a U.S based...